A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
Protein-protein interactions (PPIs) are the physical associations between proteins that underlie virtually all cellular processes — signaling, transcription, translation, metabolism, and structural organization. Structurally, PPI interfaces are large (typically 1,200-2,000 A2 buried surface area), relatively flat compared to small-molecule binding pockets, and involve complementary shapes, hydrogen bonds, salt bridges, and hydrophobic contacts. A key finding is that binding energy is not uniformly distributed across the interface — a few "hotspot" residues contribute disproportionately to binding affinity, while most interfacial residues contribute little. Understanding PPI structure is critical for drug design targeting PPIs, for engineering protein-protein recognition, and for interpreting the vast PPI networks mapped by proteomics.
Proteins rarely work alone. Enzymes form multi-subunit complexes, signaling proteins assemble into cascades through direct binding, transcription factors heterodimerize to read DNA, and the cytoskeleton is built from polymerizing protein subunits. Understanding the structural basis of protein-protein recognition — how two protein surfaces recognize and bind each other with specificity and appropriate affinity — is essential for understanding cellular function and for developing therapies that modulate these interactions.
PPI interfaces differ fundamentally from the small-molecule binding sites that traditional drug discovery targets. A typical PPI buries 1,200-2,000 A2 of surface area (compared to ~300-500 A2 for a drug binding pocket), involves 20-40 residues from each partner, and is relatively flat — lacking the deep invaginations that small molecules exploit for tight binding. The interface features a mix of complementary interactions: shape complementarity (the two surfaces fit together like puzzle pieces), hydrogen bonds (between polar groups across the interface), salt bridges (between oppositely charged residues), and hydrophobic contacts (nonpolar residues packed together at the interface center, shielded from solvent by polar peripheral residues — the "O-ring" model).
The hotspot concept, established by Clackson and Wells using alanine scanning mutagenesis of the human growth hormone receptor complex, revealed that binding energy is concentrated at a few key residues. Most interfacial residues can be mutated to alanine with minimal effect on binding affinity — they contribute to specificity (correct partner recognition) but not to the total binding energy. The hotspot residues (often tryptophan, tyrosine, arginine) are essential: mutating any one to alanine reduces binding by >2 kcal/mol (10-100x weaker binding). Hotspots are typically clustered at the center of the interface, are enriched in aromatic and charged residues, and are surrounded by peripheral residues that exclude water from the interface (maintaining the low-dielectric environment that strengthens electrostatic interactions).
The hotspot concept has therapeutic implications. If a PPI can be disrupted by targeting just the hotspot, then the "undruggable" nature of PPIs is overstated — the effective target is not the entire 2,000 A2 interface but the much smaller hotspot region, which may contain pocket-like features suitable for small-molecule binding. This insight has driven the development of PPI inhibitors — small molecules that mimic the hotspot interactions and compete with the natural binding partner. Successes include venetoclax (targeting the Bcl-2/BH3 interface in cancer), nutlins (targeting MDM2/p53), and ABT-737 analogs. These compounds represent a new frontier in drug design, enabled by structural understanding of PPI interfaces and hotspot organization.